Article
Dr. Jack Cush reviews the news and info reports the day before ACR 2025
All News
Article
Novartis announced the results of their REPLENISH trial showing the efficacy of secukinumab in adults with polymyalgia rheumatica (PMR).
Article
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have benefits beyond glycemic control, including cardioprotective and nephroprotective effects, with modest weight loss.
Article
The FDA has approved obinutuzumab (Gazyva) for the treatment of lupus nephritis. This is good news for the more than 1.7 million people worldwide with lupus nephritis.
Article
Dr. Jack Cush reviews the news and journal reports, discusses pediatric reports, pregnancy data, diet and nutrition and more.
Article
The NEJM has published a report from van Vollenhoven et al showing a new dual B cell inhibitor, telitacicept, to be effective when given to active systemic lupus erythematosus (SLE) patients; but this comes with a few safety concerns.
Janet Pope
Tweet
#AI for medical use is fast moving
governance is Impt
Protect Privacy
Facilitate trainees to LEARN
Involve #IT, ethicists, users
‘We will enter a world where all we do medically is recorded’ J Hausmann said
#ACR25 @RheumNow @ACRheum
#26S17 https://t.co/zWjy4u99Yo
Janet Pope
Tweet
#Medical #learners more optimistic re #AI than gen pop’n!
Tips
stress privacy
- pt info in AI goes to private company
All trainees will use #AI
Set boundaries - change eval where can’t use AI
only AI listening notes
👇
#cognitive #deskilling
#ACR25 @RheumNow @ACRheum
26S17 https://t.co/UzajaimOcG
David Liew
Tweet
@ACRheum SLE Treatment Guidelines 2025
Key points:
- HCQ is standard
- steroids with precision
- immunosuppressive therapies early
- shared decision making
#ACR25 @RheumNow https://t.co/AYIXE6dLlW
Dr. John Cush
Tweet
Saphnelo (anifrolumab) has been recommended for approval in EU by CHMP for systemic lupus erythematosus (on top of standard therapy) as a once-weekly pre-filled pen.
Recommendation based on TULIP-SC Phase III trial. https://t.co/UurvtLNP7S https://t.co/xeKVdVYu3z
Dr. John Cush
Tweet
RheumNow’s expanded coverage of the #ACR25 Annual Meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush
Tweet
Telitacicept Effective in Systemic Lupus Erythematosus
The NEJM has published a report from van Vollenhoven et al showing a new dual B cell inhibitor, telitacicept, to be effective when given to active systemic lupus erythematosus (SLE) patients; but this comes with a few https://t.co/L0TgynLELD
Dr. John Cush
Tweet
FDA has approved Genentech’s CD20-targeting antibody obinutuzumab (Gazyva) for the treatment of adult patients with lupus nephritis who are receiving standard therapy. https://t.co/0eGwGnSDYf https://t.co/wnQDVnTEjb
Suleman Bhana, MD
Tweet
Casal Moura, M., Merkel, P.A., Jayne, D. et al.Challenges in the diagnosis, classification and prognosis of ANCA-associated vasculitis. Nat Rev Rheumatol (2025). https://t.co/fGUr2DnfwA
Good figure, citation above. Via
@AKronbichler and colleagues https://t.co/FGfPFiGgMv
Dr. John Cush
Tweet
Colchicine Ineffective in Long COVID
Management of long COVID has been perplexing with symptoms having functional and possibly inflammatory origins. Colchicine has been studied in long COVID and failed to improve functional capacity, respiratory function, or inflammatory https://t.co/9E3dvUFqJP
Dr. John Cush
Tweet
FDA Approves Obinutuzumab for Active Lupus Nephritis
The FDA has approved obinutuzumab (Gazyva) for the treatment of lupus nephritis. This is good news for the more than 1.7 million people worldwide with lupus nephritis.
https://t.co/WbpATY86BY https://t.co/zRONkCUtIx
Dr. John Cush
Tweet
Saphnelo (anifrolumab) has been recommended for approval in EU by CHMP for systemic lupus erythematosus (on top of standard therapy) as a once-weekly pre-filled pen.
Recommendation based on TULIP-SC Phase III trial. https://t.co/VRUycfLRtf https://t.co/O7cQfkb8BU
Dr. John Cush
Tweet
FDA has approved Genentech’s CD20-targeting antibody obinutuzumab (Gazyva) for the treatment of adult patients with lupus nephritis who are receiving standard therapy. https://t.co/0eGwGnSDYf https://t.co/Z6w2iP4u3e
Dr. John Cush
Tweet
Failure of IL-17 inhibition in Lupus nephritis. 31 LN pts enrolled in phase 2 DBRPCT of secukinumab 300 mg IV, but was terminated early for futility (complete renal response at week 52 was lower with secukinumab (24.2%) than with placebo (36.3%). https://t.co/471TolqtFk https://t.co/gKi2Z2MZHS
Dr. John Cush
Tweet
Pregnancy Management in Inflammatory Bowel Disease: A Global Consensus
Consensus guidance on the management of pregnancy in patients with inflammatory bowel disease (IBD) was simultaneously published in six international journals, including The American Journal of https://t.co/F6er2mpUoV
